Drug Profile
Research programme: fibroblast growth factor receptor antagonists - Astex Pharmaceuticals/Janssen Pharmaceutica
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Astex Therapeutics
- Developer Astex Therapeutics; Cancer Research Technology; Janssen Pharmaceutica; University of Newcastle upon Tyne
- Class Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Multiple myeloma; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Multiple-myeloma in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for research development in Prostate-cancer in United Kingdom (PO)